The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C
Open accessAbstract
Interferon (IFN)-alpha has been used to investigate pathways by which innate immune cytokines influence the brain and behaviour. Previous studies suggest that altered basal ganglia function may contribute to IFN-alpha-induced neuropsychological and behavioural changes. To further examine IFN-alpha effects on neuropsychological functions related to basal ganglia (as well as other brain regions), and explore the relationship between altered neuropsychological function and IFN-alpha-induced depression and fatigue, a selected subset of the Cambridge Neuropsychological Test Automated Battery was administered to 32 hepatitis C patients at baseline (Visit 1) and following approximately 12 weeks (Visit 2) of either no treatment (n=12) or treatment with IFN-alpha plus ribavirin (n=20). Symptoms of depression and fatigue were assessed using the Montgomery-Asberg Depression Rating Scale and the Multidimensional Fatigue Inventory. Compared to control subjects, patients treated with IFN-alpha/ribavirin exhibited significant decreases in motor speed as measured in the simple and five-choice movement segments of the CANTAB reaction time task and slower response times in the rapid visual information processing task, a task of sustained attention. Decreased motor speed on the five-choice movement segments of the reaction time task was in turn correlated with increased symptoms of depression and fatigue (R=0.47, p<0.05 and R=0.48, p<0.05, respectively). IFN-alpha/ribavirin treatment had no effects on executive function, decision time in the reaction time task, or target detection accuracy in the sustained attention task. Motor slowing and its correlation with psychiatric symptoms suggest that altered basal ganglia function may contribute to the pathogenesis of IFN-alpha-induced behavioural changes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This study used IFN-α (plus ribavirin) as an inflammatory stimulus and measured planning ability with the Stockings of Cambridge task, and no effect of inflammation on planning ability was observed (Majer et al., 2008).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Majer et al., 2008
In the citing paper
“IFN-α (plus ribavirin) therapy led to significant decreases in motor speed among patients with hepatitis C (Majer et al., 2008).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Majer et al., 2008
In the citing paper
“Notably, decreased motor speed in this study was also associated with increased symptoms of depression and fatigue (Majer et al., 2008).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Majer et al., 2008
In the citing paper
“Notably, decreased motor speed in this study was also associated with increased symptoms of depression and fatigue (Majer et al., 2008).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Majer et al., 2008
In the citing paper
“The fatigue of depression, which is often a residual symptom of SSRI therapy, is a prominent feature of cytokine-induced depression, and may represent cytokine effects on the basal ganglia and dopamine (DA) function (Capuron et al., 2001, Majer et al., 2008, Capuron et al., 2009).”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Majer et al., 2008
In the citing paper
“depression and fatigue are the main side effects of treatment with IFN-α (111, 112).”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527
Smets, E. M. A., Garssen, B., Bonke, B., & de Haes, J. C. J. M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)00125-o · Cited by 3,622
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS
Mink, J. W. (1996) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00042-1 · Cited by 2,478
The Mini-Mental State Examination
Folstein, M. F. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790060110016 · Cited by 2,016
Basal ganglia and cerebellar loops: motor and cognitive circuits
Middleton, F. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00040-5 · Cited by 1,940
The Biochemical Basis of Neuropharmacology.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-575_2 · Cited by 1,882
Planning and spatial working memory following frontal lobe lesions in man
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E., & Robbins, T. W. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90137-d · Cited by 1,284
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 1×
“For example, rodent models of depression demonstrate altered mesolimbic DA system function and, importantly, certain antidepressants act to enhance DA neurotransmission (Willner et al., 1992).”
BackgroundMonchi, O., Petrides, M., Petre, V., Worsley, K., & Dagher, A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07733.2001 · Cited by 961
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Owen, A. M., Evans, A. C., & Petrides, M. (1996) · Cerebral Cortex · doi:10.1093/cercor/6.1.31 · Cited by 756
der Elst, W. V., van Boxtel, M. P. J., van Breukelen, G., & Jolles, J. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050344 · Cited by 710
Computerized assessment in neuropsychiatry using CANTAB: discussion paper.
Sahakian, B. J., & Owen, A. M. (1992) · Europe PMC (PubMed Central) · Cited by 664
Owen, A. M., Roberts, A. C., Polkey, C. E., Sahakian, B. J., & Robbins, T. W. (1991) · Neuropsychologia · doi:10.1016/0028-3932(91)90063-e · Cited by 657
Chaudhuri, A., & Behan, P. O. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00411-1 · Cited by 647
Neural systems engaged by planning: A PET study of the Tower of London task
Baker, S. C., Rogers, R. D., Owen, A. M., Frith, C. D., Dolan, R. J., Frackowiak, R. S. J., & Robbins, T. W. (1996) · Neuropsychologia · doi:10.1016/0028-3932(95)00133-6 · Cited by 635
Robbins, T. W., James-Galton, M., Owen, A. M., Sahakian, B. J., Lawrence, A. D., McInnes, L., & Rabbitt, P. (1998) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617798455073 · Cited by 629
Dissociating executive functions of the prefrontal cortex.
Robbins, T. W. (1996) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1996.0131 · Cited by 574
Coull, J. T., Frith, C. D., Frackowiak, R. S. J., & Grasby, P. M. (1996) · Neuropsychologia · doi:10.1016/0028-3932(96)00029-2 · Cited by 566
Interferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Self-citationMeyers, C. A., Albitar, M. X., & Estey, E. H. (2005) · Cancer · doi:10.1002/cncr.21234 · Cited by 459
Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine
Salamone, J. D., Correa, M., Mingote, S., & Weber, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.004 · Cited by 454
Planning and spatial working memory: A positron emission tomography study in humans
Owen, A. M., Doyon, J., Petrides, M., & Evans, A. C. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01219.x · Cited by 450
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445
Salamone, J. D., Correa, M., Mingote, S., & Weber, S. M. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035063 · Cited by 433
The Biochemical Basis of Neuropharmacology
Jellinger, K. A. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00586.x · Cited by 372
Brown, A. S., & Gershon, S. (1993) · Journal of Neural Transmission · doi:10.1007/bf01245227 · Cited by 359
Lowe, C., & Rabbitt, P. (1998) · Neuropsychologia · doi:10.1016/s0028-3932(98)00036-0 · Cited by 344
Tremblay, L. K., Naranjo, C. A., Graham, S. J., Herrmann, N., Mayberg, H. S., Hevenor, S., & Busto, U. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1228 · Cited by 340
Anatomy of the dopamine system in the basal ganglia
Smith, Y., & Kieval, J. Z. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00023-9 · Cited by 320
Mood and cognitive side effects of interferon-alpha therapy.
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998) · PubMed · Cited by 312
Lower dopamine transporter binding potential in striatum during depression
Meyer, J. H., Krüger, S., Wilson, A. A., Christensen, B. K., Goulding, V. S., Schaffer, A., Minifie, C., Houle, S., Hussey, D., & Kennedy, S. H. (2001) · Neuroreport · doi:10.1097/00001756-200112210-00052 · Cited by 269
Morón, J. A., Zakharova, I., Ferrer, J. V., Merrill, G. A., Hope, B., Lafer, E. M., Lin, Z. C., Wang, J. B., Javitch, J. A., Galli, A., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08480.2003 · Cited by 262
Neuropsychiatric Manifestations of Human Leukocyte Interferon Therapy in Patients With Cancer
Adams, F. (1984) · JAMA · doi:10.1001/jama.1984.03350070056026 · Cited by 249
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2003) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 243
Self-citationBasal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301362 · Cited by 229 · cited 4×
“…alterations (increases) in glucose metabolism in basal ganglia nuclei including the putamen, globus pallidus, and nucleus accumbens have been demonstrated in IFNalpha-treated subjects in two brain imaging studies using positron emission tomography (Juengling et al., 2000; Capuron et al., 2007).”
BackgroundMethodInfluentialSelf-citationThe phenomenology and treatment of interferon-induced depression
Loftis, J. M., & Hauser, P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.04.002 · Cited by 228
Neurological effects of recombinant human interferon.
Smedley, H. M., Katrak, M., Sikora, K., & Wheeler, T. K. (1983) · BMJ · doi:10.1136/bmj.286.6361.262 · Cited by 223
Felger, J. C., Alagbe, O., Hu, F., Mook, D., Freeman, A. A., Sanchez, M. M., Kalin, N. H., Ratti, E., Nemeroff, C. B., & Miller, A. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.026 · Cited by 214
Self-citationCancer immunotherapy: The interferon-α experience
Kirkwood, J. M. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33078 · Cited by 213
Persistent neurotoxicity of systemically administered interferon‐alpha
Meyers, C. A., Scheibel, R. S., & Forman, A. D. (1991) · Neurology · doi:10.1212/wnl.41.5.672 · Cited by 208
Martinot, M.-L. P., Bragulat, V., Artiges, E., Dollé, F., Hinnen, F., Jouvent, R., & Martinot, J.-L. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.314 · Cited by 194
Dopamine D2 receptors in depression measured with single photon emission computed tomography
D'haenen, H. A., & Bossuyt, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91202-5 · Cited by 189
Central nervous system toxicity of interferon
Rohatiner, A. Z. S., Prior, P. F., Burton, A., Smith, A. T., Balkwill, F. R., & Lister, T. A. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.63 · Cited by 183
Rabbitt, P., & Lowe, C. (2000) · Psychological Research · doi:10.1007/s004269900009 · Cited by 183
Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study
Klimek, V., Schenck, J. E., Han, H., Stockmeier, C. A., & Ordway, G. A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01383-5 · Cited by 181
Biogenic Amine Metabolites in Cerebrospinal Fluid of Depressed and Manic Patients
MENDELS, J., Frazer, A., Fitzgerald, R. G., Ramsey, T., & Stokes, J. W. (1972) · Science · doi:10.1126/science.175.4028.1380 · Cited by 179
Clinical and psychometric correlates of dopamine D2 binding in depression
SHAH, P. J., OGILVIE, A. D., GOODWIN, G. M., & EBMEIER, K. P. (1997) · Psychological Medicine · doi:10.1017/s0033291797005382 · Cited by 170
Asnis, G. M., & Garza, R. D. L. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000210099.36500.fe · Cited by 169
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology · doi:10.1212/wnl.45.5.947 · Cited by 160
Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain
Shuto, H., Kataoka, Y., Horikawa, T., Fujihara, N., & Oishi, R. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01371-6 · Cited by 151
Kynurenic acid leads, dopamine follows: A new case of volume transmission in the brain?
Wu, H., Rassoulpour, A., & Schwarcz, R. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0562-y · Cited by 151
Prefrontal cortical hypometabolism during low-dose interferon alpha treatment
Juengling, F. D., Ebert, D., Gut, O., Engelbrecht, M. A., Rasenack, J., Nitzsche, E. U., Bauer, J., & Lieb, K. (2000) · Psychopharmacology · doi:10.1007/s002130000549 · Cited by 149
Capuron, L., Ravaud, A., & Dantzer, R. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200105000-00007 · Cited by 148
Self-citationKitagami, T., Yamada, K., Miura, H., Hashimoto, R., Nabeshima, T., & Ohta, T. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02776-8 · Cited by 147
Interferon-?? in Malignant and Viral Diseases
Dorr, R. T. (1993) · Drugs · doi:10.2165/00003495-199345020-00003 · Cited by 146
Reaction Time Deficits and Parkinson's Disease
Gauntlett-Gilbert, J., & Brown, V. J. (1998) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(98)00014-1 · Cited by 142
Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and Methylphenidate
Schwartz, A. L., Thompson, J. A., & Masood, N. (2002) · Oncology nursing forum · doi:10.1188/02.onf.e85-e90 · Cited by 140
Lou, J., Kearns, G. L., Benice, T. S., Oken, B., Sexton, G. J., & Nutt, J. G. (2003) · Movement Disorders · doi:10.1002/mds.10505 · Cited by 133
Ebert, D., Loew, T. H., Feistel, H., & Pirner, A. (1996) · Psychopharmacology · doi:10.1007/bf02246416 · Cited by 133
Reichenberg, A., Gorman, J. M., & Dieterich, D. T. (2005) · AIDS · doi:10.1097/01.aids.0000192087.64432.ae · Cited by 129
Roy, A. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820060027004 · Cited by 125
Lazeron, R. H. C., Rombouts, S. A. R. B., Machielsen, W. C. M., Scheltens, P., Witter, M. P., Uylings, H. B. M., & Barkhof, F. (2000) · PubMed Central · Cited by 116
Does the immune system communicate with the central nervous system?
Dafny, N., Prieto-Gómez, B., & Reyes-Vázquez, C. (1985) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(85)80002-3 · Cited by 109
CSF amine metabolites in depression
Reddy, P. L., Khanna, S., Subhash, M. N., Channabasavanna, S. M., & Rao, B. S. S. R. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90198-9 · Cited by 108
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100
Cognitive Dysfunction and Depression During Treatment With Interferon-Alpha and Chemotherapy
Scheibel, R. S., Valentine, A. D., O'Brien, S. M., & Meyers, C. A. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.2.185 · Cited by 98
Effects of interferon alpha on performance in man: a preliminary report
Smith, A. P., Tyrrell, D. A. J., Coyle, K. B., & Higgins, P. (1988) · Psychopharmacology · doi:10.1007/bf00216072 · Cited by 97
Central nervous system changes in hepatitis C virus infection
Forton, D. M., Taylor-Robinson, S. D., & Thomas, H. C. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200604000-00005 · Cited by 87
Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes
Wichers, M., Koek, G. H., Robaeys, G., Praamstra, A. J., & Maes, M. H. J. (2004) · Psychological Medicine · doi:10.1017/s0033291704003526 · Cited by 84
Oscillations in the basal ganglia
Wichmann, T., & DeLong, M. R. (1999) · Nature · doi:10.1038/23148 · Cited by 80
Factor structure and scoring of the SKT test battery
Kim, Y. S., Nibbelink, D. W., & Overall, J. E. (1993) · Journal of Clinical Psychology · doi:10.1002/1097-4679(199301)49:1 · Cited by 78
Lieb, K., Engelbrecht, M. A., Gut, O., Fiebich, B. L., Bauer, J., Janssen, G., & Schaefer, M. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.030 · Cited by 77
Subacute sclerosing panencephalitis: remission after treatment withintraventricular interferon
PANITCH, H. S., Gómez-Plascencia, J., Norris, F. H., Cantell, K., & Smith, R. A. (1986) · Neurology · doi:10.1212/wnl.36.4.562 · Cited by 66
Processing of multiple kinematic signals in the cerebellum and motor cortices
Johnson, M. T. V., & Ebner, T. J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00027-8 · Cited by 65
Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C
Amodio, P., De Toni, E. N., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Poma, S. Z., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.09.004 · Cited by 61
Maddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., Norris, S., & Pariante, C. M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001634 · Cited by 54
Repeated Injections of Interferon-α A/D in Balb/c Mice: Behavioral Effects
Dunn, A. L., & Crnic, L. S. (1993) · Brain Behavior and Immunity · doi:10.1006/brbi.1993.1011 · Cited by 50
Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C
HILSABECK, R. C., HASSANEIN, T. I., ZIEGLER, E. A., CARLSON, M. D., & PERRY, W. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050022 · Cited by 40
Stanford, S. C., Parker, V., & Morinan, A. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90087-0 · Cited by 35
Dopamine agonists in Parkinson?s disease
Tintner, R., & Jankovic, J. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.11.1803 · Cited by 34
Cognitive Function and Quality of Life in Interferon Therapy for Melanoma
Bender, C. M., Yasko, J. M., Kirkwood, J. M., Ryan, C. M., Dunbar‐Jacob, J. M., & Zullo, T. G. (2000) · Clinical Nursing Research · doi:10.1177/10547730022158537 · Cited by 31
Sunami, M., Nishikawa, T., Yorogi, A., & Shimoda, M. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00012 · Cited by 29
Mapou, R. L., Law, W. A., Wagner, K., Malone, J. L., & Skillman, D. R. (1996) · Journal of Neuropsychiatry · doi:10.1176/jnp.8.1.74 · Cited by 27
Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-α
Ho, B. T., Huo, Y.-Y., Lu, J., Tansey, L. W., & Levin, V. A. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90446-m · Cited by 21
[Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C].
Mizoi, Y., Kaneko, H., Oharazawa, A., & Kuroiwa, H. (1997) · PubMed · Cited by 21
Sahakian, B. J. (1990) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930050402 · Cited by 20
Ribavirin May Be an Important Factor in IFN-Induced Neuropsychiatric Effects
Asnis, G. M., Garza, R. D. L., Miller, A. H., & Raison, C. L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0420b · Cited by 19
Self-citationRule-abstraction Deficits Following a Basal Ganglia Lesion
Swainson, R., & Robbins, T. W. (2001) · Neurocase · doi:10.1076/neur.7.5.433.16248 · Cited by 14
Caraceni (1998) · doi:10.1002/(sici)1097-0142(19980801)83:3
Cited by
Sorted by citations
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013) · Depression and Anxiety · doi:10.1002/da.22084 · Cited by 892
Self-citationRaison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Self-citationInflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 474
Metadata
- Authors
- Majer, M., Welberg, L. A. M., Capuron, L., Pagnoni, G., Raison, C. L., & Miller, A. H.
- Affiliations
- Emory University (US)
- Corresponding author
- Miller, Andrew H.
- Venue
- Brain, Behavior, and Immunity
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 22
- Issue
- 6
- Pages
- 870-880
- ISSN
- 0889-1591 (ISSN-L)
- PMC
- PMC2497339
- OpenAlex
- W2058231748
- Cited by
- 124
- References
- 93
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 11 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 13 · 2015: 4 · 2014: 7 · 2013: 4 · 2012: 16
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Brain Behavior and Immunity (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (UL1TR000454)
- National Heart, Lung, and Blood Institute (R01HL073921)
- National Institute of Mental Health (R01MH067990, K05MH069124)
- National Center for Research Resources (MO-1-RR-00039, M01RR000039)
- NIH Clinical Center
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- interferon-alpha, chronic hepatitis C, motor slowing, depression, fatigue, basal ganglia, neuropsychological outcomes, ribavirin, reaction time, sustained attention
- MeSH terms
- Adult, Antiviral Agents, Basal Ganglia, Depression, Fatigue, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neuropsychological Tests, Prospective Studies, Psychiatric Status Rating Scales, Reaction Time, Regression Analysis, Ribavirin, Interferon-alpha, Hepatitis C, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
